felin
infecti
periton
fip
remain
one
lead
caus
death
young
cat
pedersen
felin
infecti
periton
viru
fipv
aetiolog
agent
virul
felin
coronaviru
fcov
biotyp
demonstr
enhanc
sustain
replic
cell
monocyt
lineag
respons
trigger
perpetu
immun
mediat
patholog
seen
fip
kipar
et
al
immun
modul
drug
mainstay
treatment
affect
cat
howev
treatment
examin
control
trial
provid
littl
benefit
fischer
et
al
ritz
et
al
direct
act
antivir
therapi
fip
receiv
consider
less
clinic
attent
potenti
rnai
antivir
therapeut
demonstr
vitro
case
vivo
numer
human
veterinari
pathogen
veterinari
microbiolog
fcov
commonli
refer
felin
infecti
periton
viru
fipv
result
develop
felin
infecti
periton
fip
typic
fatal
immun
mediat
diseas
current
effect
antivir
treatment
previous
report
success
vitro
inhibit
fipv
replic
synthet
sirna
mediat
rna
interfer
rnai
immortalis
cell
line
mcdonagh
et
al
major
challeng
face
develop
antivir
strategi
resist
problem
particularli
acut
rnai
base
therapeut
due
exquisit
sequenc
specif
target
mechan
develop
resist
treatment
minimis
use
combin
therapi
rais
genet
barrier
use
highli
potent
compound
result
rapid
pronounc
reduct
viral
replic
rate
therebi
reduc
format
mutant
potenti
resist
virus
studi
investig
efficaci
combin
sirna
therapi
abil
delay
prevent
viral
escap
viru
serial
passag
cell
treat
singl
dual
sirna
rapidli
acquir
resist
mutat
identifi
sirna
target
site
combin
therapi
three
sirna
prevent
viral
escap
cours
five
passag
identifi
potent
silenc
molecul
also
compar
efficaci
term
potenc
durat
action
canon
versu
dicersubstr
sirna
two
previous
identifi
effect
viral
motif
dicersubstr
sirna
show
equival
better
potenc
canon
sirna
target
site
investig
may
appropri
molecul
vivo
use
combin
data
inform
potenti
therapeut
applic
antivir
rnai
fipv
elsevi
bv
right
reserv
divers
viral
famili
review
shah
schaffer
previous
demonstr
effect
vitro
inhibit
fipv
use
synthet
sirna
target
sequenc
encod
structur
nonstructur
protein
utr
mcdonagh
et
al
one
major
challeng
face
develop
antivir
therapeut
resist
may
develop
treatment
preexist
viru
popul
whilst
concern
antivir
compound
particularli
problemat
rnai
base
approach
due
exquisit
sequenc
specif
target
mechan
singl
nucleotid
mismatch
within
target
site
dramat
reduc
efficaci
rnaibas
viral
inhibit
impair
base
pair
guid
strand
target
gitlin
et
al
especi
relev
felin
coronavirus
known
exist
quasispeci
kiss
et
al
report
extend
previou
work
sirna
mediat
inhibit
fipv
investig
address
challeng
antivir
resist
experi
conduct
determin
efficaci
combin
sirna
therapi
fipv
abil
delay
prevent
emerg
resist
vitro
two
highli
effect
sirna
efficaci
dicersubstr
sirna
dsirna
structur
sirna
variant
report
studi
efficaci
sequenc
match
canon
sirna
investig
term
potenc
durat
action
compar
canon
sirna
target
motif
crandel
ree
felin
kidney
crfk
cell
line
propag
previous
describ
mcdonagh
et
al
fcov
fipv
wsu
purchas
american
type
cultur
collect
atcc
virginia
usa
antifcov
sirna
sequenc
tabl
design
use
previous
describ
criteria
mcdonagh
et
al
dsirna
base
previous
identifi
highli
effect
antifipv
sirna
mcdonagh
et
al
addit
nonsilenc
control
sirna
nsc
sirna
tabl
design
outlin
amarzguioui
et
al
custom
synthesis
dsirna
transfect
control
dsirna
duplex
conjug
tye
tm
integr
dna
technolog
idt
coralvil
ia
usa
resuspend
mm
nucleasefre
duplex
buffer
idt
contain
mm
potassium
acet
mm
hepe
sirna
dsirna
store
singl
use
aliquot
use
revers
transfect
conduct
per
manufactur
guidelin
use
lipofectamin
life
technolog
mulgrav
vic
australia
well
well
plate
greiner
bioon
germani
preprepar
complex
ad
well
follow
cell
well
ml
plate
cell
well
ml
plate
plate
gentli
rock
evenli
distribut
cell
incub
room
temperatur
min
minimis
edg
effect
prior
incub
h
cultur
media
remov
cell
wash
dmem
prior
infect
titrat
extracellular
viru
perform
use
method
plaqu
assay
previous
report
mcdonagh
et
al
mcdonagh
et
al
tabl
sequenc
sirna
target
fcov
posit
fcov
genom
access
number
sequenc
nonsilenc
control
sirna
nscgfp
target
gfp
also
shown
tissu
cultur
supernat
store
thaw
water
bath
clarifi
centrifug
g
min
rna
extract
use
qiaamp
viral
rna
mini
kit
qiagen
doncast
vic
australia
revers
transcript
perform
describ
mcdonagh
et
al
except
fix
volum
ml
rna
use
instead
fix
mass
cdna
store
use
pcr
primer
design
use
softwar
rozen
skaletski
flank
target
site
sirna
tabl
convent
pcr
perform
eppendorf
mastercycl
gradient
thermal
cycler
eppendorf
ml
reaction
contain
ml
gotaq
colourless
reaction
buffer
nmol
dntp
pmol
forward
revers
primer
mmol
mgcl
unit
gotaq
dna
polymeras
ml
cdna
ml
nucleasefre
water
cycl
condit
denatur
dna
min
cycl
final
extens
min
pcr
product
purifi
prior
sequenc
use
wizard
sv
gel
pcr
cleanup
system
promega
prior
purif
ml
pcr
product
electrophores
standard
wv
agaros
horizont
gel
slab
contain
ml
ml
gelr
biotium
hayward
ca
usa
tae
buffer
visualis
uv
transillumin
dolphin
view
wealtec
spark
nv
usa
confirm
singl
band
appropri
size
optic
densiti
purifi
product
measur
nm
use
nanodrop
spectrophotomet
thermo
fisher
scientif
waltham
usa
assess
sampl
concentr
puriti
purifi
pcr
product
resuspend
ng
ml
nucleasefre
water
submit
macrogen
inc
seoul
south
korea
sequenc
direct
use
abi
dna
analys
result
electropherogram
align
edit
use
geneiou
version
biomatt
ltd
auckland
nz
bioedit
sequenc
align
editor
softwar
version
experi
cell
grown
mclear
imag
plate
greiner
bioon
fix
stain
situ
fipv
antigen
express
end
infect
period
cell
fix
formaldehyd
pb
permeabilis
ice
cold
methanol
viral
antigen
detect
biotinyl
antifelin
coronavirus
fcov
antibodi
custom
monoclon
intern
sacramento
ca
usa
visualis
streptavidinconjug
alexafluor
enabl
accur
segment
cell
stain
whole
cell
stain
hc
cell
mask
blue
life
technolog
addit
dapi
life
technolog
enhanc
nuclear
visualis
fluoresc
imag
perform
use
bd
pathway
bioimag
bd
franklin
lake
nj
usa
imag
well
acquir
use
montag
laser
autofocu
perform
montag
frame
hc
cell
mask
bluedapi
imag
acquir
ex
bp
em
lp
filter
alexa
fluor
imag
acquir
ex
bp
em
lp
filter
imag
analysi
perform
use
free
opensourc
imag
analysi
softwar
cellprofil
wwwcellprofilerorg
carpent
et
al
cellprofil
pipelin
construct
measur
whole
cell
fluoresc
intens
data
export
fc
express
imag
cytometri
de
novo
softwar
lo
angel
ca
usa
analysi
calcul
percentag
infect
cell
perform
place
region
marker
fluoresc
intens
histogram
exclud
neg
cell
defin
uninfect
control
sampl
assess
efficaci
combin
treatment
crfk
cell
revers
transfect
plate
mclear
greiner
bioon
use
singl
combin
multipl
effect
antifcov
sirna
total
concentr
sirna
per
treatment
held
constant
nm
mean
treatment
involv
two
three
four
sirna
concentr
sirna
nm
nm
nm
respect
follow
transfect
cell
infect
moi
incub
co
abil
evolv
resist
rnai
mediat
inhibit
investig
serial
passag
viru
presenc
one
combin
effect
sirna
crfk
cell
revers
transfect
plate
sarstedt
use
one
combin
two
three
sirna
four
well
per
treatment
cell
transfect
nonsilenc
control
nsc
sirna
untreat
cell
includ
control
total
sirna
concentr
per
treatment
fix
nm
irrespect
number
differ
sirna
use
per
treatment
first
passag
infect
cell
infect
origin
stock
viru
moi
well
monitor
everi
h
begin
hpi
develop
cpe
three
well
particular
treatment
show
greater
cpe
cultur
media
four
well
harvest
pool
store
subsequ
passag
cell
transfect
describ
infect
ml
cultur
media
ident
treat
cell
previou
passag
clarifi
centrifug
g
min
end
experi
serial
passag
virus
titrat
plaqu
assay
consensu
sequenc
perform
determin
mutat
identifi
virus
serial
passag
sirna
treat
cell
confer
resist
phenotyp
sirna
treat
cell
infect
serial
passag
virus
cell
transfect
mock
transfect
uclear
plate
use
singl
multipl
sirna
total
sirna
concentr
per
treatment
nm
end
transfect
period
cell
infect
moi
sirna
treatment
control
duplic
well
infect
origin
stock
viru
virus
ident
treat
cell
addit
virus
cell
treat
singl
sirna
either
sirna
also
test
duplic
cell
transfect
singl
sirna
viru
previous
expos
untreat
uninfect
control
well
includ
plate
cell
fix
stain
viral
antigen
express
hpi
previous
describ
concentrationrespons
experi
perform
compar
antivir
effect
canon
dicersubstr
sirna
cell
revers
transfect
plate
sarstedt
halflog
dilut
nm
nm
singl
sirna
dsirna
potenc
combin
treatment
compar
transfect
cell
nm
nm
nm
combin
two
canon
dicersubstr
sirna
cell
transfect
nsc
sirna
dsirna
addit
untreat
cell
includ
control
end
transfect
period
cell
infect
mock
infect
moi
cultur
media
harvest
hpi
titrat
extracellular
viru
endpoint
assay
data
analysi
conduct
graphpad
prism
graphpad
prism
window
graphpad
softwar
san
diego
ca
usa
inhibitori
concentr
valu
calcul
use
inbuilt
nonlinear
curv
fit
function
follow
log
transform
compound
concentr
treatment
perform
triplic
repeat
three
independ
experi
data
repres
mean
ae
se
experi
conduct
assess
durat
antivir
action
canon
versu
dicersubstr
sirna
use
singl
combin
treatment
cell
revers
transfect
singl
dual
combin
sirna
dsirna
total
concentr
nm
end
transfect
period
cell
infect
moi
incub
co
air
cultur
media
harvest
hpi
titrat
extracellular
viru
endpoint
assay
treatment
perform
triplic
repeat
two
independ
experi
data
repres
mean
ae
se
base
extracellular
viral
titr
intracellular
viral
antigen
express
pretreat
multipl
sirna
highli
effect
inhibit
viral
replic
evid
antagonist
effect
note
concentr
test
pretreat
singl
sirna
nm
use
revers
transfect
result
reduct
extracellular
viral
titr
sirna
respect
fig
although
cell
cultur
infect
condit
differ
reduct
rel
viral
titr
use
revers
transfect
protocol
significantli
greater
previous
report
forward
transfect
cell
particularli
sirna
mcdonagh
et
al
suggest
revers
transfect
effici
deliv
sirna
crfk
cell
agreement
find
reid
et
al
pretreat
combin
two
three
four
sirna
total
concentr
nm
reduc
viral
titr
greater
test
combin
analysi
viral
antigen
express
support
find
combin
treatment
multipl
sirna
highli
effect
result
greater
reduct
percentag
infect
cell
compar
treatment
singl
sirna
fig
interestingli
percentag
infect
cell
follow
singl
treatment
sirna
respect
significantli
higher
would
expect
given
degre
inhibit
extracellular
viru
reduct
respect
larg
differ
appar
cell
treat
singli
sirna
cell
treat
sirna
combin
signific
inhibit
extracellular
viral
titr
associ
similarli
larg
reduct
percentag
infect
cell
serial
passag
cell
treat
one
multipl
sirna
associ
develop
number
singl
nucleotid
polymorph
within
sequenc
sirna
target
site
fig
viru
passag
cell
treat
singl
sirna
mutat
identifi
sirna
sirna
viru
passag
dual
tripl
sirna
treat
cell
mutat
identifi
first
respect
mutat
identifi
two
separ
locat
within
target
site
first
ctou
transit
posit
ten
viru
passag
cell
treat
sirna
alon
sirna
combin
second
ctoa
transit
posit
six
viru
passag
cell
treat
sirna
combin
sirna
target
leader
sequenc
utr
associ
amino
acid
chang
result
mutat
target
site
howev
locat
within
put
leadertr
hairpin
thought
import
cisact
element
dye
siddel
well
incorpor
sever
nucleotid
proxim
end
transcript
regulatori
sequenc
target
site
mutat
also
identifi
two
locat
posit
nine
two
polymorph
note
ctoa
transit
viru
passag
cell
treat
sirna
alon
ctog
transit
viru
passag
cell
treat
sirna
combin
second
mutat
gtoc
transit
posit
seventeen
mutat
seen
viru
passag
cell
treat
sirna
combin
nucleotid
substitut
within
target
site
associ
amino
acid
chang
although
posit
nine
target
site
correspond
wobbl
posit
codon
phenylalanin
origin
sequenc
identifi
polymorph
locat
result
amino
acid
chang
leucin
posit
seventeen
correspond
middl
base
codon
alanin
origin
sequenc
gtoc
transit
result
amino
acid
substitut
valin
base
inhibit
viral
antigen
express
identifi
mutat
result
acquisit
fulli
partial
resist
phenotyp
fig
treat
singl
sirna
acquisit
mutat
target
site
associ
almost
complet
loss
inhibit
sirna
although
ctoa
transit
note
highli
resist
phenotyp
appar
analysi
electropherogram
site
show
small
adenin
peak
addit
cytosin
suggest
subpopul
virus
undergon
mutat
first
passag
given
h
infect
period
use
studi
encompass
multipl
replic
cycl
presenc
even
lowpreval
resist
subpopul
would
like
result
appear
highli
resist
phenotyp
studi
develop
resist
sirna
mediat
inhibit
demonstr
sequenc
depend
rather
mechan
depend
virus
mutat
target
site
remain
suscept
rnai
mediat
inhibit
sirna
vice
versa
data
shown
mutat
appar
viru
passag
dual
combin
sirna
treat
cell
partial
resist
phenotyp
note
rel
viral
antigen
express
increas
mutat
present
target
site
accompani
increas
rel
viral
antigen
express
interestingli
rel
viral
antigen
express
dual
treat
virus
remain
approxim
despit
presenc
appar
fix
mutat
target
site
complet
resist
seen
viru
passag
tripl
combin
sirna
treat
cell
remain
suscept
rnai
mediat
inhibit
five
passag
although
low
level
resist
appar
despit
earli
appear
low
level
resist
mutat
identifi
target
region
ctou
transit
identifi
posit
ten
target
possibl
ctog
transit
identifi
posit
nine
target
although
electropherogram
latter
site
show
two
almost
equal
peak
mutat
target
site
remain
posit
nine
target
revert
c
although
small
g
peak
evid
suggest
subpopul
virus
retain
mutat
second
novel
mutat
target
ctou
transit
posit
seventeen
identifi
none
mutat
present
onward
appear
confer
signific
increas
resist
compar
earlier
passag
rel
potenc
rnai
trigger
investig
studi
shown
target
depend
target
site
dsirna
potent
sirna
valu
nm
respect
fig
tabl
target
valu
dsirna
sirna
similar
nm
respect
dual
combin
dsirna
consider
potent
dual
combin
sirna
almost
reduct
valu
nm
compar
nm
base
shape
timerespons
curv
gener
durat
antivir
respons
similar
sirna
dsirna
design
target
fig
overal
durat
antivir
respons
appear
relat
sirna
potenc
target
pretreat
dsirna
result
almost
complet
inhibit
viral
replic
hpi
follow
rapid
rise
extracellular
viral
titr
reach
maximum
titr
approxim
equal
untreat
cell
hpi
pretreat
sirna
result
similar
respons
although
case
degre
inhibit
hpi
lower
seen
dsirna
pretreat
comparison
extracellular
viral
titr
untreat
cell
cell
pretreat
nsc
sirna
dsirna
data
shown
similar
rise
rapidli
hpi
peak
hpi
declin
similar
pictur
seen
cell
pretreat
dual
combin
sirna
dsirna
although
case
magnitud
peak
viral
titr
treat
cell
lower
untreat
cell
nsc
sirnadsirna
treat
cell
molecul
target
previous
demonstr
less
potent
demonstr
shorter
durat
action
peak
viral
titr
occur
hpi
present
studi
investig
abil
fcov
develop
resist
sirna
mediat
inhibit
strategi
minimis
shown
rapid
emerg
resist
follow
sirna
treatment
monotherapi
resist
popul
identifi
follow
singl
passag
cell
treat
sirna
combin
therapi
sirna
significantli
delay
emerg
resist
treatment
combin
sirna
may
effect
delay
prevent
emerg
resist
virus
due
low
probabl
multipl
simultan
mutat
occur
due
rapid
pronounc
reduct
viral
replic
rate
hodg
field
whilst
theoret
addit
antivir
ad
treatment
regimen
reduc
likelihood
resist
occur
treatment
must
balanc
potenti
increas
toxic
antagonist
effect
rnaibas
therapeut
addit
sirna
compet
access
risc
machineri
thu
combin
therapi
multipl
sirna
may
result
highli
potent
sirna
dilut
presenc
less
potent
molecul
bitko
et
al
castanotto
et
al
similarli
competit
incorpor
risc
sirna
endogen
microrna
may
increas
risk
offtarget
effect
current
studi
support
notion
fipv
combin
therapi
sirna
target
least
three
independ
region
requir
interest
extens
combinatori
therapi
approach
minimis
emerg
resist
treatment
use
combin
contain
highli
effect
sirna
addit
number
sirna
design
recognis
inhibit
like
escap
sequenc
target
region
socal
second
gener
sirna
current
studi
despit
target
conserv
region
select
pressur
due
sirna
treatment
result
gener
two
uniqu
mutat
three
uniqu
mutat
larg
scale
screen
escap
sequenc
would
requir
determin
whether
mutat
identifi
current
small
scale
studi
repres
like
rout
viral
escap
also
whether
approach
practic
target
base
overal
number
escap
sequenc
possibl
recent
studi
use
approach
hiv
shown
although
viral
escap
via
mutat
target
second
gener
sirna
inhibit
select
pressur
result
develop
resist
via
altern
rout
schopman
et
al
structur
doublestrand
rna
molecul
respons
mediat
rnai
nucleotid
duplex
two
nucleotid
overhang
end
strand
often
refer
structur
elbashir
et
al
chemic
synthesis
sirna
tradit
design
mimic
structur
central
nucleotid
duplex
complementari
target
sequenc
overhang
commonli
deoxythymidin
search
improv
efficaci
reduc
offtarget
effect
rang
nonclass
sirna
structur
variant
investig
appear
offer
advantag
canon
structur
chang
et
al
kim
et
al
rose
et
al
salomon
et
al
one
nt
duplex
refer
dicersubstr
sirna
shown
kim
et
al
time
potent
sequenc
match
canon
sirna
without
induc
interferon
protein
kinas
r
respons
enhanc
durat
action
refin
origin
bluntend
duplex
result
dsirna
structur
use
current
studi
nucleotid
sens
strand
two
termin
nucleotid
replac
dna
nt
antisens
strand
hybridis
give
blunt
end
sens
terminu
nt
overhang
sens
terminu
amarzguioui
et
al
asymmetri
incorpor
dna
base
dsirna
structur
result
preferenti
incorpor
antisens
strand
risc
improv
complex
format
protein
known
import
rnai
well
minimis
activ
innat
immun
respons
amarzguioui
et
al
snead
et
al
publish
data
howev
support
content
dicersubstr
sirna
offer
advantag
canon
sirna
base
foster
et
al
compar
perform
dsirna
sirna
rang
target
found
class
effect
canon
dicersubstr
sirna
compar
term
potenc
durat
activ
vitro
vivo
dicersubstr
sirna
also
report
less
toler
chemic
modif
immunostimulatori
howev
regard
antivir
therapi
latter
may
actual
desir
featur
stewart
et
al
current
studi
rel
efficaci
canon
dicersubstr
sirna
vari
target
site
monotherapi
target
combin
treatment
dsirna
potent
littl
differ
sirna
dsirna
monotherapi
target
increas
potenc
greatest
combin
therapi
dual
combin
dsirna
almost
lower
dual
sirna
therapi
durat
action
appear
relat
potenc
molecul
increas
potenc
result
increas
durat
activ
previou
studi
investig
durat
activ
canon
versu
dicersubstr
sirna
target
cellular
gene
case
cessat
silenc
thought
relat
reduct
intracellular
sirna
due
activ
ribonucleas
dilut
effect
caus
cell
divis
takahashi
et
al
current
studi
appar
cessat
antivir
effect
may
also
due
emerg
resist
isol
simpl
overwhelm
rnai
machineri
cell
expos
progress
higher
moi
viral
replic
proce
hypothes
fit
experiment
data
show
prolong
durat
activ
correl
increas
potenc
potenti
limit
studi
lack
test
divers
rang
fipv
isol
viru
use
current
studi
type
ii
fcov
preval
type
ii
fcov
vari
worldwid
howev
report
studi
infect
type
virus
common
pedersen
unlik
higher
preval
type
infect
would
invalid
therapeut
applic
sirna
test
studi
primari
differ
type
ii
fcov
spike
protein
region
target
test
sirna
furthermor
sirna
select
base
homolog
report
strain
includ
type
type
ii
fcov
subsequ
align
sirna
target
recent
publish
sequenc
confirm
high
degre
conserv
among
type
current
studi
previou
work
author
suggest
sirna
dsirna
mediat
rnai
especi
combin
therapi
target
least
three
region
mayb
worthi
investig
therapeut
option
fip
treatment
